How should aplastic anemia be managed with eltrombopag (Promacta) and cyclosporine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Aplastic Anemia with Eltrombopag (Promacta) and Cyclosporine

For severe aplastic anemia, the combination of eltrombopag with cyclosporine (with or without ATG) significantly improves hematologic response rates and should be used as first-line therapy, while for moderate aplastic anemia, adding eltrombopag to cyclosporine alone achieves superior response rates compared to cyclosporine monotherapy.

Treatment Approach by Disease Severity

Severe Aplastic Anemia (SAA)

Standard Regimen:

  • Horse ATG + Cyclosporine + Eltrombopag is the preferred first-line therapy for patients not eligible for stem cell transplantation 1
  • This triple combination achieves:
    • Complete response at 3 months: 22% (vs 10% with ATG/cyclosporine alone)
    • Overall response at 6 months: 68% (vs 41% without eltrombopag)
    • Median time to first response: 3.0 months (vs 8.8 months without eltrombopag)

ATG-Free Alternative:

  • Eltrombopag + Cyclosporine alone (without ATG) is an effective option when ATG is unavailable or not tolerated 2
  • Achieves 46% overall hematologic response by 6 months
  • Particularly valuable in resource-limited settings or for patients who cannot tolerate ATG infusion reactions

Moderate Aplastic Anemia (MAA)

First-Line Treatment:

  • Eltrombopag + Cyclosporine achieves significantly better outcomes than cyclosporine alone 3
  • Overall response rate at 24 weeks: 71.4% (vs 42.5% with placebo + cyclosporine)
  • For patients without complete response after 24 weeks of cyclosporine alone, adding eltrombopag improves response to 73.5% by week 48

Dosing Protocols

Eltrombopag Dosing

  • Initial dose: 150 mg daily (100 mg for Asian patients) 2
  • Pediatric dosing: 50 mg daily for patients >6 years; 25 mg daily for ages 1-5 years 4
  • Therapeutic concentration range: 2.5-4.0 μg/mL in pediatric patients 5
    • Below 2.5 μg/mL: suboptimal efficacy
    • Above 4.0 μg/mL: increased adverse effects
  • Maximum dose: 75 mg/day should not be exceeded in chronic use 4

Cyclosporine Dosing

  • Initial dose: 10 mg/kg/day orally, divided into two doses 2
  • Target trough level: 200-400 μg/L 2
  • Duration: Continue for 6 months with eltrombopag, then taper based on response 3

Treatment Duration

  • Initial treatment phase: 6 months of combination therapy 3, 2
  • Response assessment: Evaluate at 3 and 6 months
  • Continuation: If responding, continue eltrombopag; cyclosporine can be tapered after 6 months 3

Monitoring Requirements

Hematologic Monitoring

  • Complete blood counts: Weekly initially, then every 2-4 weeks once stable
  • Bone marrow examination: At baseline, 6 months, and if disease progression suspected 6
  • Response criteria:
    • Partial response: Platelet count >50 × 10⁹/L
    • Complete response: Platelet count >100 × 10⁹/L 4

Safety Monitoring

Cyclosporine-specific 7:

  • Serum creatinine and BUN every 2 weeks initially, then monthly
  • Blood pressure monitoring (risk of hypertension)
  • Liver function tests
  • Drug level monitoring (trough levels)

Eltrombopag-specific 2:

  • Serum bilirubin (41% of patients develop elevation)
  • Alanine aminotransferase (22% develop elevation)
  • Monitor for thrombotic events

Somatic Mutation Surveillance

  • Baseline mutation testing recommended 1
  • 29-31% of patients have detectable mutations at baseline
  • Increases to 55-66% at 6 months, but does not affect hematologic response or 2-year outcomes
  • Annual monitoring for clonal evolution to myelodysplastic syndrome

Critical Drug Interactions

Drugs that INCREASE cyclosporine levels (requiring dose reduction) 7:

  • Calcium channel blockers (diltiazem, verapamil, nicardipine)
  • Azole antifungals (fluconazole, itraconazole, ketoconazole)
  • Macrolide antibiotics (erythromycin, clarithromycin)
  • Avoid grapefruit juice entirely

Drugs that DECREASE cyclosporine levels (requiring dose increase) 7:

  • Rifampin, rifabutin
  • Anticonvulsants (carbamazepine, phenobarbital, phenytoin)
  • St. John's Wort must be avoided (causes marked reduction in cyclosporine levels)

Expected Outcomes and Relapse Management

Response Rates

  • With triple therapy (ATG + cyclosporine + eltrombopag): 68% overall response at 6 months 1
  • With eltrombopag + cyclosporine (no ATG): 46-71% overall response depending on disease severity 3, 2
  • Event-free survival at 2 years: 46% with eltrombopag vs 34% without 1

Relapse Management

  • Relapse rate: 21.2% after median 14 months following eltrombopag discontinuation 8
  • For relapsed/refractory disease: Re-initiate eltrombopag, which remains effective in 52.7% at 12 months 8

Common Pitfalls to Avoid

  1. Do not use eltrombopag in MDS patients with >5% marrow blasts 9 - risk of transient blast increase
  2. Do not abruptly discontinue eltrombopag - taper gradually to minimize relapse risk 4
  3. Do not combine cyclosporine with bosentan - causes 50% reduction in cyclosporine levels 7
  4. Monitor renal function closely - cyclosporine nephrotoxicity occurs in 21-30% with prolonged use 7
  5. All blood products must be irradiated and filtered in aplastic anemia patients 6

Special Populations

Pediatric patients:

  • Therapeutic drug monitoring essential - target eltrombopag concentration 2.5-4.0 μg/mL 5
  • Lower initial doses required (see dosing section above)

Elderly patients:

  • Increased risk of cyclosporine nephrotoxicity - monitor renal function more frequently 7
  • Consider dose adjustments based on creatinine clearance

Refractory/relapsed disease:

  • Eltrombopag remains effective even after IST failure 10, 8
  • Response rates: 52.7-60% at 6-12 months in refractory cases

References

1
Research

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

The New England journal of medicine, 2022

Related Questions

What is the appropriate management for a patient with aplastic anemia presenting with neutropenic sepsis?
What are the causes of heterogeneous anemia?
What hemoglobin level defines severe anemia?
What are the key considerations and potential interactions when taking Danazol (Danazol) 200mg twice daily, Eltrombopag (Eltrombopag) 100mg once in the morning, and Cyclosporine (Cyclosporine) 100mg twice daily, including timing, meals, monitoring, and duration of treatment?
How should aplastic anemia be managed, considering severity, patient age, and donor availability?
What is the recommended treatment for acute otitis media in otherwise healthy adults?
How long after taking omeprazole should a patient take Cymbalta (duloxetine)?
Compare the two laboratory panels (first: glucose 163 mg/dL, blood urea nitrogen 29 mg/dL, creatinine 0.6 mg/dL, BUN‑to‑creatinine ratio 50, sodium 130 mmol/L, potassium 4.4 mmol/L, chloride 97 mmol/L, CO₂ 27 mmol/L, calcium 8.9 mg/dL, estimated glomerular filtration rate >90 mL/min/1.73 m²; second: glucose 184 mg/dL, blood urea nitrogen 26 mg/dL, creatinine 0.5 mg/dL, BUN‑to‑creatinine ratio 55, sodium 135 mmol/L, potassium 4.3 mmol/L, chloride 103 mmol/L, CO₂ 25 mmol/L, calcium 9.2 mg/dL, estimated glomerular filtration rate >90 mL/min/1.73 m²) to assess dehydration?
What is the first-line management for a patient with chronic venous insufficiency?
Can rosuvastatin cause worsening depression?
Given two sets of labs showing hyperglycemia, markedly elevated blood urea nitrogen with a very high BUN/creatinine ratio, mild hyponatremia, low‑normal chloride, normal potassium, CO₂, calcium, and preserved estimated glomerular filtration rate, what is the most likely diagnosis and what immediate management steps should be taken?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.